Introduction {#Sec1}
============

Patients with end-stage renal disease (ESRD) have a high risk of fractures. The risk of hip fractures is four times higher in patients on dialysis compared with the general population \[[@CR1]\]. While hip fractures are mostly clinically apparent, many vertebral fractures are presented atypically \[[@CR2]\]. Vertebral fractures are easily missed on radiographs \[[@CR3]\]. Hence, they often remain undiagnosed, but even undiagnosed vertebral fractures negatively impact physical functioning \[[@CR4]\], quality of life \[[@CR5]\], and mortality risk \[[@CR6]\]. Nevertheless, due to poor documentation in cohorts and dialysis registries, the risk of vertebral fracture in ESRD remains largely unknown \[[@CR7]\].

Patients with ESRD have distinct risk factors for fracture beyond traditional risk factors due to chronic kidney disease-mineral and bone disorder \[[@CR7]\]. The disturbed bone metabolism, also known as renal osteodystrophy, comprises a spectrum of loss of bone mass due to high bone turnover and microstructural abnormalities due to suppressed bone turnover \[[@CR8]\]. These specific types of renal osteodystrophy cannot be distinguished with conventional markers of bone fragility, such as bone mineral density (BMD) \[[@CR9]\]. Clinicians commonly rely on parathyroid hormone (PTH) to estimate bone turnover in ESRD; however, the prognostic utility of BMD and PTH for fracture risk in ESRD is unclear \[[@CR10]\]. A recent meta-analysis indicated that lower BMD at the lumbar spine was associated with prevalent fractures among patients on dialysis, but not in age-adjusted analyses \[[@CR11]\]. This suggests that vertebral BMD may not independently predict fracture risk in ESRD. Furthermore, studies observed that both low and high PTH values were associated with hip and vertebral fracture risk among patients with ESRD, but with various cut-off values \[[@CR12]--[@CR15]\]. There is also an unclear relationship of PTH with BMD, with three studies of in total 289 patients on dialysis reporting negative associations of PTH with BMD at cortical sites (such as the distal radius), but inconsistent associations with BMD at trabecular sites (such as the spine) \[[@CR16]--[@CR18]\].

In this study, we determined vertebral fracture prevalence in patients on dialysis using lateral chest radiographs and determined vertebral fracture incidence in patients with follow-up radiographs, who remained on dialysis or received a kidney transplant. We examined the relationships of vertebral trabecular BMD and PTH with the risk of vertebral fracture and additionally the relationship of PTH with vertebral trabecular BMD.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

We used data from the NOCTx study, a prospective cohort that compared progression of coronary artery calcification between patients treated with different renal replacement therapies. Between December 2009 and February 2016, NOCTx recruited 181 patients from eight centers in the Netherlands, who were on chronic hemodialysis or peritoneal dialysis with a minimum dialysis duration of 2 months, who were on hemodialysis and switched to nocturnal hemodialysis, or who were on dialysis and received a kidney transplant. At inclusion, all dialysis patients were eligible for transplantation. NOCTx included patients between 18 and 75 years and excluded patients with a life expectancy \< 3 months or pre-emptive transplantation. All subjects gave written informed consent. NOCTx has been approved by the Medical Ethics Committee of the University Medical Center Utrecht and was conducted in accordance with the declaration of Helsinki.

Patients were treated according to the KDIGO guidelines by their attending nephrologist \[[@CR10]\]. Conventional hemodialysis was delivered 3× 4--5 h per week in-center with default 3.0 mEq/L dialysate calcium. Peritoneal dialysis was delivered as continuous ambulant peritoneal dialysis (*n* = 16) or automated peritoneal dialysis (*n* = 8) with default 2.5 mEq/L dialysate calcium. Nocturnal hemodialysis was delivered ≥ 4× 8 h per week at home with default 3.0 mEq/L dialysate calcium. Kidney transplant recipients received standard immunosuppressant regimens consisting of tacrolimus, mycophenolate mofetil, and prednisone in tapering doses (cumulative dose in first 2 months typically 1.0--1.4 g, maintenance dose 5--7.5 mg/day from 3 months post-transplantation). Acute rejections were treated with 3× 1 g of methylprednisolone intravenously.

We studied vertebral fracture prevalence in patients that underwent a lateral chest radiograph as part of routine care within 6 months of inclusion in NOCTx (*n* = 148). For kidney transplant recipients, this was the screening radiograph performed the day of transplantation. We excluded two patients because of poor-quality radiographs leaving a sample of 146 patients. We studied associations of PTH in all patients with no history of parathyroidectomy and non-missing PTH values (*n* = 131). We assessed the incidence of vertebral fractures in patients that underwent a second lateral chest radiograph as part of routine care \> 1 year after the first radiograph during maximum 3 years follow-up (*n* = 70).

BMD measurements {#Sec4}
----------------

In NOCTx, all patients underwent non-enhanced cardiac multi-slice computed tomography (CT) at inclusion, using a single iCT 256 scanner (Philips Medical Systems, Best, the Netherlands), which is checked for image quality and stability at least once every 2 weeks as part of our quality assurance system. The acquisition parameters were as follows: 120 kV, 40--50 mAs, rotation time 270 ms, and 128 × 0.625 mm collimation; table height was set by the attending medical physicist in order to position the patient in the isocenter of the gantry. A single reader (TJ) determined volumetric trabecular BMD of three consecutive thoracic vertebrae in the T7--T10 range \[[@CR19]\]. The reader placed a region of interest (ROI) at the center of the vertebra and changed its placement to exclude the cortical edge, bone islands, large veins, or calcified herniated disks, or excluded a vertebra entirely if it was fractured (*n* = 6). We calculated BMD in milligram per centimeter cube by multiplying the mean CT value per patient (in Hounsfield units) with a calibration factor of 0.871 (calibration factor coefficient of variation 6.1%) \[[@CR20]\]. With this iCT 256 scanner-specific calibration factor, vertebral trabecular BMD can be measured accurately without a phantom, correlating highly with phantom-based BMD values (*r* = 0.987) \[[@CR20]\].

In a random sample of 85 scan re-reads by the same reader, the 95% limits of agreement were − 7.6 (95% CI − 8.4 to − 6.8) and 11.5 (95% CI 10.7 to 12.3) mg/cm^3^, and intra-observer reliability (ICC~agreement~) was 0.99. In previous studies, the interscan variation has been shown to be low (2.8%) \[[@CR19]\].

Parathyroid hormone {#Sec5}
-------------------

Parathyroid hormone was measured as part of routine care at clinical laboratories, with intact 2-site immunoassays (Beckman-Coulter, Fullerton, USA; Abbott Diagnostics, Abbott Park, USA; or Roche Diagnostics, Indianapolis, USA). Reference intervals of these assays are 1.3--9.3 pmol/L, 1.6--7.2 pmol/L, and 1.6--6.9 pmol/L, respectively. PTH values were averaged over measurements of the 3 months preceding the first lateral chest radiograph (mostly two measurements (60%), range 1--4 measurements).

Vertebral fracture assessment {#Sec6}
-----------------------------

Using lateral chest radiographs, which show the thoracic and upper lumbar spine, two trained physicians (TJ and NG) independently identified vertebral fractures and graded them according to Genant's semiquantitative method \[[@CR21]\]. This method allows to exclude other possible causes of vertebral deformity, such as Scheuermann's disease, remodeling of vertebral bodies due to degenerative disk disease, or scoliosis. Lateral chest radiographs are reliable for the diagnosis of vertebral fractures, with excellent agreement and reliability compared with lateral spine radiographs (95--98% and 0.88--0.91, respectively) \[[@CR22]\]. Fractures were graded by type (wedge, biconcave, or crush deformity) and severity: grade 1 (20--25% height loss), grade 2 (25--40% height loss), or grade 3 (\> 40% height loss). All radiographs were re-read in consensus readings and verified by an expert geriatrician (HW). On average, we evaluated 10.8 ± 1.4 vertebrae per patient, which included the seventh thoracic vertebra in 145 (99%) patients and the first lumbar vertebra in 124 (85%) patients. The prevalence of vertebral fractures did not differ significantly between patients with ≤ 10 evaluable vertebrae (18/61 fractures) and patients with \> 10 evaluable vertebrae (32/85 fractures) (*P* = 0.40).

We defined the incidence of a fracture as any new vertebral fracture not present on the first radiograph or deterioration of an existing fracture to a higher grade. We defined the follow-up time as the time between the first and second radiographs. We evaluated an average of 10.6 ± 1.3 vertebrae per patient, which included the seventh thoracic vertebra in all patients and the first lumbar vertebra in 53 (76%) patients.

Other study variables {#Sec7}
---------------------

At inclusion, study personnel recorded demographics at the University Medical Center Utrecht. Body mass index was calculated by dividing weight (kg) by height (m^2^), based on chart review. Smoking status was self-reported and categorized as current and non-current smoking. Biochemical parameters (total calcium, albumin, phosphate, C-reactive protein, and total alkaline phosphatase) were measured in clinical laboratories in the 8 recruiting centers, and values were averaged over measurements of 3 months preceding inclusion (commonly 2--3 measurements). Medication use and medical history were assessed by chart review. We defined dialysis duration as the time between the first day of dialysis and the inclusion date, minus the time with a functioning kidney transplant, expressed in months.

Statistical analyses {#Sec8}
--------------------

We reported normally distributed variables as mean (± standard deviation), non-normally distributed variables as median (interquartile range, IQR), and categorical data as number (percentage). We tabulated patient characteristics according to vertebral fracture prevalence. We categorized PTH as tertiles, as we expected a U-shaped relationship with vertebral fracture \[[@CR7]\].

We evaluated associations of kidney transplantation versus dialysis with vertebral fracture incidence, of vertebral trabecular BMD with vertebral fracture prevalence, and lastly of PTH tertiles with both vertebral fracture prevalence and vertebral trabecular BMD. For vertebral fracture prevalence and incidence as outcome measure, we used Poisson regression due to the high event rate and reported relative risks (RR) with 95% confidence intervals (CI) \[[@CR23]\]. For vertebral fracture prevalence as outcome measure, we adjusted for potential confounders age (years), sex, dialysis duration (months), and diabetes (type I or type II/absent). For vertebral fracture incidence as outcome measure, we adjusted for age (years), sex, and follow-up time (years), and stratified by dialysis or kidney transplantation, as we suspected distinct fracture etiologies. For vertebral trabecular BMD as outcome measure, we used linear regression and adjusted for potential confounders as described above.

To evaluate the continuous associations of PTH with vertebral fracture prevalence and vertebral trabecular BMD, we constructed P-splines adjusted for age (years) and sex \[[@CR24]\]. We considered *P* values ≤ 0.05 (two-tailed) statistically significant and used R 3.4.1 (R Foundation Statistical Computing) for all analyses.

Sensitivity analyses {#Sec9}
--------------------

To test the robustness of the associations, we repeated the analyses of the association of PTH with vertebral fracture prevalence stratified by age (\< 50 or ≥ 50 years); sex; history of diabetes, cardiovascular disease, current smoking, or transplantation; treatment with hemodialysis or peritoneal dialysis; use of prednisone; calcium-containing phosphate binders; vitamin D analogues; and cinacalcet. Furthermore, we repeated the analyses of the association of vertebral trabecular BMD with vertebral fracture prevalence excluding grade 1 fractures.

Results {#Sec10}
=======

Study population {#Sec11}
----------------

The mean age of the study population (*n* = 146*)* was 52 ± 13 years, 98 (67%) were male, median dialysis duration was 26 (IQR 13--55) months, and 18 (12%) had diabetes. Eighteen patients (12%) were on long-term corticosteroids (low-dose up to 10 mg/day), while none used bisphosphonates and 23 (18%) used cinacalcet.

Patients that could not be evaluated for vertebral fractures (*n* = 35) due to missing radiographs were similar in patient characteristics: mean age 51 ± 14 years, 23 (66%) were male, median dialysis duration was 31 (IQR 15--74) months, and eight (23%) had diabetes (Table [S1](#MOESM2){ref-type="media"}).

Vertebral fracture prevalence and incidence {#Sec12}
-------------------------------------------

In total, 50 patients (34%) had 84 prevalent vertebral fractures. Patients with prevalent vertebral fractures were older, more often male, had longer dialysis durations, and more often used cinacalcet than patients without prevalent vertebral fractures (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the 146 patients with end-stage renal disease stratified by prevalence of a vertebral fracture on lateral chest radiographNo vertebral fracture\
(*n* = 96)Prevalent vertebral fracture\
(*n* = 50)Demographics and medical history  Age (years)50 ± 1357 ± 12  Male (%)58 (60%)40 (80%)  Body mass index (kg/m^2^)25.6 ± 4.626.0 ± 4.4  Diabetes mellitus (%)13 (14%)5 (10%)  Cardiovascular disease (%)22 (23%)12 (24%)  Current smoker (%)7 (7%)8 (16%)History of kidney disease  Dialysis duration (months)21 (11--48)38 (19--70)  Previous transplantation (%)20 (21%)16 (32%)  Parathyroidectomy (%)4 (4%)5 (10%)  Cause of end-stage renal disease (%)    Cystic kidney disease16 (17%)11 (22%)    Interstitial nephritis2 (2%)2 (4%)    Glomerulonephritis27 (28%)11 (22%)    Vascular disease18 (19%)14 (28%)    Diabetic nephropathy6 (6%)3 (6%)    Other13 (14%)5 (10%)    Unknown14 (15%)4 (8%)  Dialysis treatment (%)    Hemodialysis68 (71%)40 (80%)    Peritoneal dialysis28 (29%)10 (20%)Medication use at inclusion\*  Corticosteroids (%)10 (10%)8 (16%)  Calcium-containing phosphate binders (%)30 (36%)11 (26%)  Vitamin D analogues (%)64 (77%)32 (74%)  Cinacalcet (%)10 (12%)13 (30%)Laboratory parameters  Calcium (mmol/L)2.34 ± 0.142.35 ± 0.13  Phosphate (mmol/L)1.36 ± 0.541.32 ± 0.48  Parathyroid hormone (pmol/L)17 (10--34)18 (9--49)  C-reactive protein (mg/L)3 (2--6)3 (2--9)  Total alkaline phosphatase (IU/L)83 (69--114)73 (59--96)Bone mineral density and vertebral fracture  Vertebral bone mineral density (mg/cm^3^)139 ± 41120 ± 44  Number of vertebral fractures (%)    One--27 (54%)    Two--14 (28%)    Three--7 (14%)    Four--2 (4%)  Highest vertebral fracture grade (%)    Grade 1--32 (64%)    Grade 2--16 (32%)    Grade 3-2 (4%)Results are presented as mean ± standard deviation, median (interquartile range) or percentage\*Data on medication use (except for corticosteroid use) were available in 126 patients

We assessed incident vertebral fractures in a subset of 70 patients: 47 who continued treatment with dialysis and 23 who received a kidney transplant at inclusion. The kidney transplant recipients (*n* = 23) had a mean estimated glomerular filtration rate of 54 ± 19 mL/min/1.73m^2^.

Patients that could not be evaluated for incident vertebral fractures (*n = 76*) were similar in patient characteristics: mean age 51 ± 13 years, 23 (70%) were male, median dialysis duration was 31 (IQR 16--64) months, and 9 (12%) had diabetes. Furthermore, these patients were similar regarding treatment modality (38 patients on hemodialysis, 13 on peritoneal dialysis, 25 kidney transplant recipients versus 35, 12, and 23, respectively) and vertebral fracture prevalence (27/76 patients, 36% versus 23/70, 33%).

After a median follow-up of 1.8 years (IQR 1.3--2.7) or 137 person-years, 20 patients (29%) developed 24 new vertebral fractures. Compared with patients without incident vertebral fracture, patients with incident vertebral fracture were older (mean 60 versus 52 years) and had more often a previous vertebral fracture (55% versus 24%) (Table [2](#Tab2){ref-type="table"}). Patient characteristics of patients that received a kidney transplant (*n* = 23) and patients that remained on dialysis (*n* = 47) were comparable (Table [S2](#MOESM3){ref-type="media"}), although the use of corticosteroids and bisphosphonates during follow-up was higher among kidney transplant recipients (100% versus 21% and 17% versus none). The risk of incident vertebral fracture did not differ significantly for kidney transplant recipients (6/23 with incident vertebral fracture) compared with patients on dialysis (14/47 with incident vertebral fracture) after adjustment for age, sex, and follow-up time (adjusted RR for kidney transplant recipients compared with patients on dialysis 0.94, 95% CI 0.32 to 2.43).Table 2Characteristics of the subset of 70 patients with end-stage renal disease who had follow-up radiographs, stratified by incidence of vertebral fractureNo incident vertebral fracture\
(*n* = 50)Incident vertebral fracture\
(*n* = 20)Demographics and medical history  Age (years)52 ± 1360 ± 13  Male (%)31 (62%)14 (70%)  Diabetes mellitus (%)7 (14%)2 (10%)  Current smoker (%)5 (10%)0History of kidney disease  Dialysis duration (months)18 (10--39)25 (18--50)  Renal replacement therapy during follow-up (%)    Hemodialysis24 (48%)11 (55%)    Peritoneal dialysis9 (18%)3 (15%)    Kidney transplant17 (34%)6 (30%)Medication use during follow-up  Corticosteroids (%)\*26 (52%)7 (35%)  Bisphosphonates (%)3 (6%)1 (5%)  Calcium-containing phosphate binders (%)24 (48%)7 (35%)  Vitamin D analogues (%)27 (54%)12 (60%)  Cinacalcet (%)4 (8%)5 (25%)Bone mineral density and vertebral fracture  Vertebral bone mineral density (mg/cm^3^)132 ± 39119 ± 36  Previous vertebral fracture (%)12 (24%)11 (55%)  Deterioration of existing fracture to higher grade (%)--1 (5%)  Number of new vertebral fractures (%)    One--16 (80%)    Two--2 (10%)    Three--1 (5%)  Highest incident vertebral fracture grade (%)    Grade 1--14 (70%)    Grade 2--5 (25%)    Grade 3--1 (5%)Results are presented as mean ± standard deviation, median (interquartile range), or percentage\*Acute rejections, treated with high doses of methylprednisolone, occurred in 3 patients who did not sustain a vertebral fracture, and in 2 patients who did sustain a vertebral fracture

Associations of vertebral trabecular BMD with vertebral fracture {#Sec13}
----------------------------------------------------------------

Mean vertebral trabecular BMD was 139 ± 41 mg/cm^3^ in patients without a prevalent vertebral fracture (*n* = 96) and 120 ± 44 mg/cm^3^ in patients with a prevalent vertebral fracture (*n* = 50). Vertebral trabecular BMD was associated with a lower risk of vertebral fracture prevalence in unadjusted models 0.93 (95% CI 0.86 to 0.99) but not when adjusted for potential confounders 0.97 (95% CI 0.89 to 1.04) (Table [S3](#MOESM4){ref-type="media"}). These associations were numerically similar when grade 1 fractures (*n* = 32) were excluded (unadjusted 0.90, 95% CI 0.79 to 1.01; and adjusted 0.95, 95% CI 0.83 to 1.06).

Associations of PTH with vertebral fracture and vertebral trabecular BMD {#Sec14}
------------------------------------------------------------------------

One hundred thirty-one patients had no history of parathyroidectomy and non-missing PTH values (Table S4). Vertebral fractures were the least prevalent in patients in the middle PTH tertile (16% versus 38% and 43%; *P* \< 0.05) (Table [3](#Tab3){ref-type="table"}). Compared with the middle tertile, the adjusted RR of vertebral fracture prevalence was 2.28 for the lowest tertile (95% CI 0.97 to 5.97) and 2.82 for the highest tertile (95% CI 1.22 to 7.27). Correspondingly, the continuous association of PTH with prevalent vertebral fracture risk appeared U-shaped, with the lowest risk around 29 pmol/L (Fig. [1](#Fig1){ref-type="fig"}). Notably, patients in the lowest tertile had significantly lower total alkaline phosphatase levels (median 69 versus 85 and 91 IU/L, *P* = 0.02).Table 3Associations of parathyroid hormone with vertebral bone mineral density and vertebral fractures in a subset of 131 patients with end-stage renal diseaseParathyroid hormoneLowest tertile\
(*n* = 45)Middle tertile\
(*n* = 44)Highest tertile\
(*n* = 42)PTH (pmol/L)7 (5--10)19 (16--23)50 (36--66)Alkaline phosphatase (IU/L)69 (57--89)85 (73--105)91 (69--126)Vertebral fracture prevalence*17 (38%)7 (16%)18 (43%)*  Excluding grade 1 fractures*5 (11%)09 (21%)*Relative risk  Crude model2.37 (1.02 to 6.14)1.00 (ref)2.69 (1.17 to 6.93)  Model 12.16 (0.92 to 5.61)1.00 (ref)2.80 (1.22 to 7.20)  Model 22.28 (0.97 to 5.97)1.00 (ref)2.82 (1.22 to 7.27)Vertebral BMD (mg/cm^3^)*116 ± 38130 ± 35148 ± 38*Difference (mg/cm^3^)  Crude model− 13.6 (− 29.0 to 1.8)0.00 (ref)18.7 (3.0 to 140.5)  Model 1− 9.4 (− 22.5 to 3.7)0.00 (ref)14.2 (1.0 to 27.5)  Model 2− 9.7 (− 22.7 to 3.3)0.00 (ref)14.6 (1.4 to 27.8)Values are mean ± standard deviation, median (interquartile range), percentage, relative risks estimated with the Poisson regression (with 95% confidence intervals), or linear regression coefficients (with 95% confidence intervals)*PTH* parathyroid hormone, *BMD* bone mineral densityModel 1: age (years) and sexModel 2: model 1 + dialysis duration (months) and diabetes (type I or type II/absent)Vertebral fracture prevalence: p = 0.02Excluding grade 1 fractures: p \< 0.01Vertebral BMD: p \< 0.01Fig. 1Continuous associations of parathyroid hormone with risk of prevalent vertebral fracture in 131 patients with end-stage renal disease, adjusted for age and sex. A histogram of parathyroid hormone is shown at the bottom

We repeated these analyses stratified by various patient characteristics (Table [S5](#MOESM6){ref-type="media"}), which all showed similar trends. The U-shaped association of PTH with vertebral fracture risk appeared even stronger in vitamin D analogues users (*n* = 87) (adjusted RR 3.68, 95% CI 1.12 to 16.52 for the lowest and 3.57, 95% CI 1.14 to 15.61 for the highest PTH tertile). Patient characteristics were similar between vitamin D analogue users and non-users (Table [S6](#MOESM6){ref-type="media"}), except for higher phosphate (1.49 versus 1.19 mmol/L) and PTH values (23 versus 11 pmol/L) among vitamin D analogue users.

In the lowest PTH tertile, vertebral trabecular BMD tended to be lower with linear regression compared with the middle tertile (adjusted regression coefficient − 9.7 mg/cm^3^, 95% CI − 22.7 to 3.3), while in the highest tertile vertebral trabecular BMD was significantly higher (14.6 mg/cm^3^, 95% CI 1.4 to 27.8) (Table [3](#Tab3){ref-type="table"}). For the continuous associations, lower PTH values tended to track with lower vertebral trabecular BMD values (Figure [S1](#MOESM1){ref-type="media"}).

Discussion {#Sec15}
==========

Our study indicates that vertebral fractures have a high prevalence (34%) and incidence (29% after median 1.8 years follow-up) in a relatively young population (mean age 52 years) of patients with ESRD. Also, our data show no relationship of CT-measured vertebral trabecular BMD with vertebral fracture and suggest a U-shaped relationship of PTH with vertebral fracture.

The vertebral fracture prevalence in our study is remarkably high compared with the general population. In a population-based study of European men and women aged 50--54 years, the prevalence ranged between 5 and 17% as determined with morphometric approaches \[[@CR25]\], and between 2 and 11% in a population-based study of Dutch men and women aged 45--59 years as determined with algorithm-based qualitative methods and a morphometric approach \[[@CR26]\]. In general, reproducibility is highest with algorithm-based qualitative methods \[[@CR27]\], followed by Genant's semiquantitative technique used by us, which in turn has higher reproducibility than morphometric approaches (e.g., the McCloskey and Eastell methods and quantitative morphometry) \[[@CR28]\]. Considering, vertebral fracture prevalence in our ESRD cohort is more than twice as high as in the general population, which could have been even higher if we had also evaluated the lower lumbar spine.

The prevalence of vertebral fractures is poorly documented in cohorts and dialysis registries \[[@CR7]\] and has been reported in only few studies of patients on dialysis \[[@CR29]\]. Four studies reported prevalences between 21 and 33% for patients generally older (mean ages between 54 and 69 years) \[[@CR14], [@CR30]--[@CR32]\], whereas one study reported 9% vertebral fractures without mentioning age of the study population or method of vertebral fracture assessment \[[@CR33]\] and another study reported 11% vertebral fractures among slightly younger incident kidney transplant recipients (49.7 versus 52.2 years), although it was unclear whether only the lumbar spine was evaluated \[[@CR34]\]. In general, our estimates might be higher due to geographic variation in vertebral fracture prevalence between Northern and Southern Europe \[[@CR25]\] or different referral patterns for dialysis \[[@CR35]\]. Also, one of these studies used stricter criteria for wedge fractures (the most common type of vertebral fracture \[[@CR26]\]) only adjudicating grade 2 and 3 fractures \[[@CR14]\], and another study did not specify vertebral fracture adjudication method \[[@CR34]\]. Yet another study found 55% vertebral fractures in older patients on hemodialysis (mean 64 years old) but used quantitative morphometry \[[@CR36]\]. We employed Genant's semiquantitative technique to adjudicate fractures, which allows to exclude other possible causes of vertebral deformity \[[@CR21]\] and has a higher reproducibility than morphometric approaches used in previous studies \[[@CR28]\]. This supports the high vertebral fracture prevalence of 34% we currently report.

Our study is the first to report vertebral fracture incidence in patients with ESRD using radiographs to assess vertebral fractures. Two previous studies reported 4.8 \[[@CR12]\] and about 10 \[[@CR37]\] vertebral fractures per 1000 person-years in patients on dialysis, with vertebral fractures identified by *International Classification of Diseases, Ninth revision (ICD-9)* codes in claim files of the United States Renal Data system. However, this methodology is likely to underestimate vertebral fracture incidence because of clinical underdiagnosis \[[@CR3]\]. We used standardized methods by 2 independent trained physicians to adjudicate fractures, which is much more sensitive than ICD-9 codes. Our data indicate a high vertebral fracture incidence (146 per 1000 person-years) among patients with ESRD. Although causes of vertebral fracture may differ for patients on dialysis and kidney transplant recipients, our data showed similar vertebral fracture rates for both groups, far exceeding rates reported in placebo groups of large osteoporosis drug trials \[[@CR38]\]. This high incidence warrants a better understanding of the impact of mineral metabolism disturbances on bone strength in order to prevent these fractures.

In this first study to measure vertebral trabecular BMD with cardiac CT in patients with ESRD, we did not find associations of vertebral trabecular BMD with vertebral fracture, similar to a previous study using quantitative CT \[[@CR32]\]. Cardiac CT vertebral trabecular BMD correlates well with quantitative CT lumbar spine BMD (*r =* 0.91--0.93) \[[@CR19]\], which is considered a useful and appropriate method for BMD testing \[[@CR39], [@CR40]\]. The discrepancy between vertebral trabecular BMD and fracture might be explained by physiological anabolic effects of PTH, which are most pronounced on trabecular bone \[[@CR41]\]. Indeed, we found an association of higher PTH with higher vertebral trabecular BMD, whereas previous studies reported inconsistent associations \[[@CR16]--[@CR18]\]. Because of this, vertebral trabecular BMD may not be useful to assess fracture risk in ESRD. Moreover, our findings indicate that BMD testing is redundant in these patients. The clinical purpose of BMD is to identify high-risk patients for fracture, but with the currently reported vertebral fracture risk, patients on dialysis can all be regarded as high-risk patients for fracture and rather may benefit from radiographic screening for vertebral fractures.

Our data suggest a U-shaped association of PTH with vertebral fracture risk. We used continuous associations to indicate the precise direction of the associations per PTH picomoles per liter. This allowed us to estimate the shape of fracture risk for the whole range of PTH compared with predefined PTH categories or quantiles, indicating the lowest vertebral fracture risk around 29 pmol/L. Our finding complements previous studies reporting optimal PTH values for fracture risk around 32 pmol/L \[[@CR12]\], above 21 pmol/L \[[@CR13]\], above 7 pmol/L \[[@CR14]\], between 16 and 32 pmol/L \[[@CR15]\], and below 95 pmol/L \[[@CR42]\]. In order to draw conclusions about the target PTH range in clinical practice, randomized controlled trials are needed to define optimal PTH values for fracture.

Our results should be interpreted within certain limitations. We used lateral chest radiographs and not spine radiographs, which may have complicated vertebral fracture diagnosis, although lateral chest radiographs have excellent agreement and reliability compared with spine radiographs \[[@CR22]\]. Also, lateral chest radiographs did not allow for fracture assessment of the lower lumbar spine, as we could only evaluate the spine down to the first lumbar vertebra in most patients. Nevertheless, one could even expect a higher prevalence of vertebral fractures with additional lumbar spine radiography. Furthermore, the radiographs were performed as part of routine care, which may have introduced indication bias. However, only two radiographs (1%) were performed with the indication of back pain. Another limitation is that the majority of our study population was male, while it has been indicated that the inter-observer agreement is not good for the diagnosis of vertebral fracture in males \[[@CR43]\]. Further limitations include that PTH was measured with multiple assays, that we did not additionally measure vertebral BMD using conventional dual-energy X-ray absorption (DXA), and that we did not have data on historical corticosteroid use or vitamin D status. Notwithstanding, most patients used vitamin D analogues, rendering vitamin D deficiency unlikely as cause of vertebral fractures. Finally, all patients in this study were eligible for transplantation and some were treated with home hemodialysis. This population may therefore be somewhat healthier than the average dialysis population. On the other hand, a high vertebral fracture risk in our population indicates an even higher risk in the general dialysis population.

This study has several strengths. We adjudicated fractures on radiographs based on 2 independent trained physicians, instead of recall of fracture history or radiographic reports. We thus also detected less severe fractures, corroborating the high vertebral fracture prevalence. Also, the patients on dialysis and kidney transplant recipients were well comparable, as all dialysis patients were eligible for transplantation, and all kidney transplant recipients were on dialysis before transplantation.

In conclusion, even relatively young and healthy patients with ESRD are at high risk of vertebral fractures. CT-measured vertebral trabecular BMD is not associated with vertebral fracture and may therefore not be useful to assess fracture risk in ESRD. Rather, patients may benefit from radiographic screening for vertebral fractures. Nevertheless, our study did not measure vertebral BMD using DXA and assessed vertebral fractures using lateral chest radiographs and not spine radiographs. The association of PTH with vertebral fracture risk appears to be U-shaped, with the lowest risk around 29 pmol/L. The target PTH range for fracture needs investigation by randomized controlled trials.
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